Cargando…

Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women

INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planne...

Descripción completa

Detalles Bibliográficos
Autores principales: Cetin, Esra Can, Guven, Suleyman, Sal, Hidayet, Guvendag Guven, Emine Seda, Mentese, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297632/
https://www.ncbi.nlm.nih.gov/pubmed/34321985
http://dx.doi.org/10.5114/pm.2021.106089
_version_ 1783725896891367424
author Cetin, Esra Can
Guven, Suleyman
Sal, Hidayet
Guvendag Guven, Emine Seda
Mentese, Ahmet
author_facet Cetin, Esra Can
Guven, Suleyman
Sal, Hidayet
Guvendag Guven, Emine Seda
Mentese, Ahmet
author_sort Cetin, Esra Can
collection PubMed
description INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate). RESULTS: The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy. CONCLUSIONS: These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months’ use, serum IMA levels returned to baseline levels after 12 months’ use. Based on this study’s findings, long-term use of HT may not have a positive effect on cardiovascular disease protection.
format Online
Article
Text
id pubmed-8297632
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-82976322021-07-27 Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women Cetin, Esra Can Guven, Suleyman Sal, Hidayet Guvendag Guven, Emine Seda Mentese, Ahmet Prz Menopauzalny Original Paper INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate). RESULTS: The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy. CONCLUSIONS: These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months’ use, serum IMA levels returned to baseline levels after 12 months’ use. Based on this study’s findings, long-term use of HT may not have a positive effect on cardiovascular disease protection. Termedia Publishing House 2021-05-23 2021-06 /pmc/articles/PMC8297632/ /pubmed/34321985 http://dx.doi.org/10.5114/pm.2021.106089 Text en Copyright: © 2021 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Cetin, Esra Can
Guven, Suleyman
Sal, Hidayet
Guvendag Guven, Emine Seda
Mentese, Ahmet
Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title_full Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title_fullStr Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title_full_unstemmed Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title_short Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
title_sort serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297632/
https://www.ncbi.nlm.nih.gov/pubmed/34321985
http://dx.doi.org/10.5114/pm.2021.106089
work_keys_str_mv AT cetinesracan serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen
AT guvensuleyman serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen
AT salhidayet serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen
AT guvendagguvenemineseda serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen
AT menteseahmet serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen